Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Pharmacokinetic-Guided Prophylaxis with Rurioctocog Alfa Pegol Improves Bleeding Rates over Standard Prophylaxis: Real-World Observational Data from the Ahead German Study

Robert Klamroth, Karin Kurnik, Swee Wenning, Carmen Escuriola-Ettingshausen, Stephan Regensburger, Leilei Tang, Joan Gu, Randy Guerra, Johannes Oldenburg

Blood (2021) 138 (Supplement 1): 3187.

https://doi.org/10.1182/blood-2021-146162

Published: 2021

Journal Articles

Effectiveness and Safety Outcomes in Patients with Hemophilia a Receiving Antihemophilic Factor (Recombinant) for at Least 5 Years in a Real-World Setting: 6-Year Interim Analysis of the Ahead International and German Studies

Dimitrios A. Tsakiris, MD, Johannes Oldenburg, Robert Klamroth, Benoît Guillet, Kate Khair, Angela Huth-Kühne, MD, Karin Kurnik, Stephan Regensburger, Jaco Botha, Alejandro Fernandez, Leilei Tang, Margareth C. Ozelo

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-139873

Published: 2020

Journal Articles

Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A

H. Marijke van den Berg, Kathelijn Fischer, Manuel Carcao, Hervé Chambost, Gili Kenet, Karin Kurnik, Chris Königs, Christoph Male, Elena Santagostino, Rolf Ljung

Blood (2019) 134 (3): 317–320.

https://doi.org/10.1182/blood.2019000658

Published: 2019

Includes: Supplemental data

Journal Articles

99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry

Blood (2018) 132 (Supplement 1): 2472.

https://doi.org/10.1182/blood-2018-99-114518

Published: 2018

Journal Articles

Population Pharmacokinetics Profiling to Tailor Prophylaxis in Hemophilia a Patients: A Pilot Feasibility Study

Michaela Stemberger, Felix Kallenbach, Elisabeth Schmit, Alanna McEneny-King, Andrea N Edginton, PhD, Alfonso Iorio, MD PhD, Karin Kurnik

Blood (2017) 130 (Supplement 1): 2404.

https://doi.org/10.1182/blood.V130.Suppl_1.2404.2404

Published: 2017

Journal Articles

Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study

Blood (2016) 128 (22): 3774.

https://doi.org/10.1182/blood.V128.22.3774.3774

Published: 2016

Journal Articles

Comparison of Rethrombosis-Free Survival in Children Versus Adults Suffering from Antithrombin-, Protein C- and Protein S-Deficiency: An Observational Multicenter Cohort Study

Verena Limperger, MD, Gili Kenet, MD, Christine Heller, MD, Ralf Knoefler, MD, Karin Kurnik, MD, Ulrich C Klostermeier, MD, Rolf Mesters, MD, Neil A Goldenberg, MD PhD, Guy Young, MD, Ulrike Nowak-Gottl, MD

Blood (2015) 126 (23): 2316.

https://doi.org/10.1182/blood.V126.23.2316.2316

Published: 2015

Journal Articles

Characterization of Patients with Glanzmann Thrombasthenia and Identification of 17 Novel Mutations

Kirstin Sandrock-Lang, PhD, Johannes Oldenburg, MD PhD, Verena Wiegering, MD, Susan Halimeh, MD, Sentot Santoso, Karin Kurnik, Lars Fischer, Dimitrios Tsakiris, MD, Michael Sigl-Kraetzig, Brigit Brand, MD, Katharina Kraetzer, Niklas Deeg, Eileen Busse, Zieger Barbara

Blood (2014) 124 (21): 1460.

https://doi.org/10.1182/blood.V124.21.1460.1460

Published: 2014

Journal Articles

Impact of SERPINC1, PROC and PROS1 Mutations on the Thrombotic Phenotype in Children with Venous Thromboembolism: An Observational Multicenter Cohort Study

Verena Limperger, Gili Kenet, MD, Christine Heller, MD, Karin Kurnik, Ralf Knoefler, Rolf M Mesters, MD, Susan Halimeh, MD, Ulrike Nowak-Göttl

Blood (2014) 124 (21): 583.

https://doi.org/10.1182/blood.V124.21.583.583

Published: 2014

Journal Articles

Self- and Parent/Proxies-Reported Health-Related Quality Of Life In Children and Adolescents With Bleeding Disorders: Cross Sectional Investigation and Comparison With Healthy Siblings and Healthy Peers

Neuner Bruno, Sylvia von Mackensen, PhD, Susan Halimeh, MD, Susanne Holzhauer, MD, Robert Klamroth, MD, PhD, Karin Kurnik, MD, Anne Kruempel, MD, Michael Fruewald, Henning Krampe, Ulrike Nowak-Goettl

Blood (2013) 122 (21): 4773.

https://doi.org/10.1182/blood.V122.21.4773.4773

Published: 2013

Journal Articles

The EPIC Study: A Clinical Trial To Assess Whether Early Low Dose Prophylaxis In The Absence Of Immunological Danger Signals Reduces Inhibitor Incidence In Previously Untreated Patients (PUPs) With Hemophilia A

Guenter Auerswald, MD, Karin Kurnik, MD, Jan Blatny, MD, PhD, Armin J Reininger, MD

Blood (2013) 122 (21): 576.

https://doi.org/10.1182/blood.V122.21.576.576

Published: 2013

Journal Articles

Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study

Blood (2013) 121 (20): 4046–4055.

https://doi.org/10.1182/blood-2012-09-457036

Published: 2013

Includes: Supplemental data

Journal Articles

The risk of hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type 2

Blood (2013) 121 (15): 2943–2951.

https://doi.org/10.1182/blood-2012-10-463166

Published: 2013

Includes: Supplemental data

Journal Articles

A genome-wide association study identifies a gene network of ADAMTS genes in the predisposition to pediatric stroke

Astrid Arning, Milan Hiersche, Anika Witten, Gerhard Kurlemann, Karin Kurnik, Daniela Manner, Monika Stoll, Ulrike Nowak-Göttl

Blood (2012) 120 (26): 5231–5236.

https://doi.org/10.1182/blood-2012-07-442038

Published: 2012

Includes: Supplemental data

Journal Articles

Influence of Factor V G1691A or Prothrombin G20210A Mutation On Inhibitor Development in Patients with Severe Hemophilia A - an Israeli-German Database Study.

Gili Kenet, MD, Christoph Bidlingmaier, Carmen Escuriola Ettingshausen, MD, Sven Gutsche, MD, Susan Halimeh, MD, Verena Janssen, MD, Karin Kurnik, MD, Ulrike Nowak-Gottl, MD

Blood (2012) 120 (21): 2234.

https://doi.org/10.1182/blood.V120.21.2234.2234

Published: 2012

Journal Articles

Patients with Hermansky-Pudlak Syndrome Show Various Phenotypes Caused by Novel Mutations,

Kirstin Sandrock, PhD, Karin Kurnik, MD, Stephan Ehl, MD, Christoph Bidlingmaier, Lea Nakamura, Nina Rombach, MD, Sophie Schäfer, MD, Barbara Zieger, MD

Blood (2011) 118 (21): 3286.

https://doi.org/10.1182/blood.V118.21.3286.3286

Published: 2011

Journal Articles

Impact of Treatment Intensity and Factor VIII Products On the Development On High Titre Inhibitors in Children with Severe Hemophilia A: Results of a Non-Concurrent Cohort Study.

Karin Kurnik, MD, Susan Halimeh, MD, Daniela Manner, MD, Susanne Holzhauer, MD, Carmen Escuriola Ettingshausen, MD, Rosemarie Schobess, MD, Ulrike Nowak-Gottl, MD

Blood (2009) 114 (22): 1303.

https://doi.org/10.1182/blood.V114.22.1303.1303

Published: 2009

Journal Articles

New Early Prophylaxis Regimen That Avoids Immunological Danger Signals Can Reduce Factor Eight (FVIII) Inhibitor Development Independent From Product Type Used.

Guenter K.H. Auerswald, MD, Christoph Bidlingmaier, Werner Engl, Heidi Chehadeh, Birgit M Reipert, PhD, Karin Kurnik, MD

Blood (2009) 114 (22): 221.

https://doi.org/10.1182/blood.V114.22.221.221

Published: 2009

Journal Articles

Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.

Alfonso Iorio, MD, Susan Halimeh, MD, Christoph Bidlingmaier, MD, Leonardo R. Brandao, MD, Carmen Escuriola-Ettingshausen, MD, Neil A Goldenberg, MD, PhD, Alessandro Gringeri, MD, MSc, Susanne Holzhauer, MD, Gili Kenet, MD, PhD, Ralf Knoefler, MD, Wolfhart Kreuz, MD, Karin Kurnik, MD, Daniela Manner, MD, Emanuela Marchesini, MD, Maura Marcucci, MD, Elena Santagostino, MD, PhD, Guy Young, MD, Pier Mannuccio Mannucci, MD, Ulrike Nowak-Gottl, MD

Blood (2009) 114 (22): 3154.

https://doi.org/10.1182/blood.V114.22.3154.3154

Published: 2009

Journal Articles

Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies.

Blood (2009) 114 (22): 3993.

https://doi.org/10.1182/blood.V114.22.3993.3993

Published: 2009

NARROW

Pharmacokinetic-Guided Prophylaxis with Rurioctocog Alfa Pegol Improves Bleeding Rates over Standard Prophylaxis: Real-World Observational Data from the Ahead German Study

Effectiveness and Safety Outcomes in Patients with Hemophilia a Receiving Antihemophilic Factor (Recombinant) for at Least 5 Years in a Real-World Setting: 6-Year Interim Analysis of the Ahead International and German Studies

Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A

99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry

Population Pharmacokinetics Profiling to Tailor Prophylaxis in Hemophilia a Patients: A Pilot Feasibility Study

Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study

Comparison of Rethrombosis-Free Survival in Children Versus Adults Suffering from Antithrombin-, Protein C- and Protein S-Deficiency: An Observational Multicenter Cohort Study

Characterization of Patients with Glanzmann Thrombasthenia and Identification of 17 Novel Mutations

Impact of SERPINC1, PROC and PROS1 Mutations on the Thrombotic Phenotype in Children with Venous Thromboembolism: An Observational Multicenter Cohort Study

Self- and Parent/Proxies-Reported Health-Related Quality Of Life In Children and Adolescents With Bleeding Disorders: Cross Sectional Investigation and Comparison With Healthy Siblings and Healthy Peers

The EPIC Study: A Clinical Trial To Assess Whether Early Low Dose Prophylaxis In The Absence Of Immunological Danger Signals Reduces Inhibitor Incidence In Previously Untreated Patients (PUPs) With Hemophilia A

Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study

The risk of hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type 2

A genome-wide association study identifies a gene network of ADAMTS genes in the predisposition to pediatric stroke

Influence of Factor V G1691A or Prothrombin G20210A Mutation On Inhibitor Development in Patients with Severe Hemophilia A - an Israeli-German Database Study.

Patients with Hermansky-Pudlak Syndrome Show Various Phenotypes Caused by Novel Mutations,

Impact of Treatment Intensity and Factor VIII Products On the Development On High Titre Inhibitors in Children with Severe Hemophilia A: Results of a Non-Concurrent Cohort Study.

New Early Prophylaxis Regimen That Avoids Immunological Danger Signals Can Reduce Factor Eight (FVIII) Inhibitor Development Independent From Product Type Used.

Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.

Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only